2023 World Conference on Lung Cancer (Posters)-EP07.04. Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-Small Cell Lung Cancer

EP07.04. Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to compare the pathologic outcomes of different neoadjuvant regimens in resectable locally advanced non-small cell lung cancer (NSCLC). The study analyzed data from the nationwide Flatiron Health database, which includes electronic health records. The cohort included 47 patients who received neoadjuvant chemotherapy, chemo-radiotherapy, or chemo-immunotherapy.<br /><br />The analysis showed that the use of neoadjuvant chemotherapy and chemo-radiotherapy decreased over time, while the use of chemo-immunotherapy increased. Male patients were more likely to receive chemo-immunotherapy. The study found that pathologic complete response (pCR) rates were comparable between chemo-radiotherapy and chemo-immunotherapy, with pCR achieved in 42.9% and 37.5% of patients, respectively. Compared to chemotherapy, there was a non-significant trend towards higher pCR rates for both chemo-radiotherapy and chemo-immunotherapy.<br /><br />The multivariable analysis confirmed these findings, showing similar odds ratios for chemo-radiotherapy and chemo-immunotherapy compared to chemotherapy. However, there was no significant difference in pCR rates between chemo-radiotherapy and chemo-immunotherapy. The authors suggest that further analysis stratified by programmed death-ligand 1 (PD-L1) status may help inform clinical decision-making for patients with resectable NSCLC.<br /><br />In conclusion, this preliminary analysis suggests that neoadjuvant chemo-immunotherapy and chemo-radiotherapy may have comparable pCR rates in resectable locally advanced NSCLC. As neoadjuvant chemo-immunotherapy becomes more common, further research on pathologic response and survival outcomes stratified by PD-L1 status is needed to guide clinical decision-making for these patients.

Asset Subtitle

Nicholas Wells

Meta Tag

Speaker Nicholas Wells

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

neoadjuvant regimens

pathologic outcomes

resectable NSCLC

Flatiron Health database

chemo-immunotherapy

pCR rates

multivariable analysis

PD-L1 status

clinical decision-making

survival outcomes